Record Details

Catalog Search

Search The Catalog


Repurposing therapeutic drugs for COVID-19 : research challenges and opportunities : hearing before the Subcommittee on Investigations and Oversight of the Committee on Science, Space, and Technology, House of Representatives, One Hundred Sixteenth Congress, second session, June 19, 2020. Cover Image E-book

Repurposing therapeutic drugs for COVID-19 : research challenges and opportunities : hearing before the Subcommittee on Investigations and Oversight of the Committee on Science, Space, and Technology, House of Representatives, One Hundred Sixteenth Congress, second session, June 19, 2020.

United States. Congress. House. Committee on Science, Space, and Technology (2011- ). Subcommittee on Investigations and Oversight, (author.).

Electronic resources

Click for online content.

Record details

  • Physical Description: 1 online resource (iii, 75 pages) : illustration
  • Publisher: Washington : U.S. Government Publishing Office, 2021.

Content descriptions

General Note:
"Serial no. 116-74."
Access ID (govinfo): CHRG-116hhrg40634.
GPO Cataloging Record Distribution Program (CRDP).
Bibliography, etc. Note:
Includes bibliographical references.
Participant or Performer Note:
Hearing witnesses: Dr. Peter Lurie, President, Center for Science in the Public Interest; Dr. James Finigan, Director of the Respiratory Centers of Excellence, National Jewish Health; Dr. Rick L. Stevens, Associate Laboratory Director for Computing, Environment and Life Sciences, Argonne National Laboratory; Dr. Benjamin Rome, Associate Physician, Brigham and Women's Hospital; Postdoctoral Research Fellow, Harvard Medical School.
Date/Time and Place of an Event Note:
Date of hearing: 2020-06-19.
Source of Description Note:
Description based on online resource; title from PDF title page (govinfo, viewed Feb. 3, 2021).

Search for related items by subject

Subject:
COVID-19 (Disease) > Treatment > United States.
COVID-19 (Disease) > United States.
Drugs > Research > United States.
Genre:
Legislative hearings.

Accessibility Features

Awards, Reviews, & Suggested Reads

Shelf Browser

MARC Record

LDR 02665nam a2200457 i 4500
00112896767
003CARDINAL
00520210205103634.0
006m o d f
007cr |||||||||||
008210205s2021 dcua ob f000 0 eng c
0248 . ‡a40-634 ‡q(GPO jacket number)
035 . ‡a(OCoLC)1236207366
037 . ‡bMARCIVE CRDP
040 . ‡aGPO ‡beng ‡erda ‡epn ‡cGPO ‡dMvI
042 . ‡apcc
043 . ‡an-us---
050 4. ‡aKF27 ‡b.S39 2020d
074 . ‡a1025-A-03 (online)
0860 . ‡aY 4.SCI 2:116-74
088 . ‡aSerial no. 116-74 (United States. Congress. House. Committee on Science, Space, and Technology (2011-))
1101 . ‡aUnited States. ‡bCongress. ‡bHouse. ‡bCommittee on Science, Space, and Technology (2011- ). ‡bSubcommittee on Investigations and Oversight, ‡eauthor.
24510. ‡aRepurposing therapeutic drugs for COVID-19 : ‡bresearch challenges and opportunities : hearing before the Subcommittee on Investigations and Oversight of the Committee on Science, Space, and Technology, House of Representatives, One Hundred Sixteenth Congress, second session, June 19, 2020.
264 1. ‡aWashington : ‡bU.S. Government Publishing Office, ‡c2021.
300 . ‡a1 online resource (iii, 75 pages) : ‡billustration
336 . ‡atext ‡btxt ‡2rdacontent
337 . ‡acomputer ‡bc ‡2rdamedia
338 . ‡aonline resource ‡bcr ‡2rdacarrier
500 . ‡a"Serial no. 116-74."
500 . ‡aAccess ID (govinfo): CHRG-116hhrg40634.
500 . ‡aGPO Cataloging Record Distribution Program (CRDP).
504 . ‡aIncludes bibliographical references.
5110 . ‡aHearing witnesses: Dr. Peter Lurie, President, Center for Science in the Public Interest; Dr. James Finigan, Director of the Respiratory Centers of Excellence, National Jewish Health; Dr. Rick L. Stevens, Associate Laboratory Director for Computing, Environment and Life Sciences, Argonne National Laboratory; Dr. Benjamin Rome, Associate Physician, Brigham and Women's Hospital; Postdoctoral Research Fellow, Harvard Medical School.
518 . ‡aDate of hearing: 2020-06-19.
588 . ‡aDescription based on online resource; title from PDF title page (govinfo, viewed Feb. 3, 2021).
650 0. ‡aCOVID-19 (Disease) ‡xTreatment ‡zUnited States.
650 0. ‡aCOVID-19 (Disease) ‡zUnited States.
650 0. ‡aDrugs ‡xResearch ‡zUnited States. ‡0(CARDINAL)294694
655 7. ‡aLegislative hearings. ‡2lcgft ‡0(CARDINAL)323144
85640. ‡uhttps://purl.fdlp.gov/GPO/gpo151186 ‡7govdoc ‡yClick for online content. ‡9BHM ‡9BLADEN ‡9BRASWELL ‡9BROWN ‡9BRUNSWICK ‡9BUNCOMBE ‡9BURKE ‡9CALDWELL ‡9CARTERET ‡9CASWELL ‡9CLEVELAND ‡9DAVIE ‡9DUPLIN ‡9FARMVILLE ‡9FORSYTH ‡9FRANKLIN ‡9GRANVILLE ‡9HARNETT ‡9HAYWOOD ‡9HENDERSON ‡9IREDELL ‡9JOHNSTON ‡9LEE ‡9MADISON ‡9MAUNEY ‡9NANTAHALA ‡9NORTHWESTERN ‡9ONSLOW ‡9PERRY ‡9PERSON ‡9POLK ‡9ROBESON ‡9ROCKINGHAM ‡9RUTHERFORD ‡9SAMPSON ‡9SANDHILL ‡9SCOTLAND ‡9STANLY ‡9TRV ‡9WARREN ‡9YANCEY ‡9DEQ_ELC ‡9GHL ‡9GOV_MANSION ‡9HIGH_POINT ‡9NC_ARCHIVES ‡9NC_ART ‡9NC_DOL ‡9NC_DOT ‡9NC_LEG ‡9NC_NATSCI ‡9NC_SHS ‡9CAMDEN ‡9CURRITUCK ‡9DARE ‡9JACKSON ‡9PASQUOTANK
901 . ‡a12896767 ‡bgovdoc-script b7cc8217318ed179a9b601401ae2627ceed36cc7 5456ba2a0c02faccf1b7d9f48f4fb905396b96c0 ‡c12896767 ‡tbiblio ‡selectronic